Description: Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Home Page: www.biohavenpharma.com
BHVN Technical Analysis
215 Church Street
New Haven,
CT
06510
United States
Phone:
203 404 0410
Officers
| Name | Title |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman & CEO |
| Mr. Matthew Buten | Chief Financial Officer |
| Mr. George C. Clark | VP & Chief Accounting Officer |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| Ms. Jennifer Porcelli | VP of Investor Relations |
| Mr. Warren Volles | Gen. Counsel & Chief Legal Officer |
| Mr. Clifford Bechtold M.S. | Chief Compliance Officer |
| Ms. Kimberly Gentile | Sr. VP of Clinical Operations |
| Mr. John Tilton | Chief Commercial Officer of Rare Diseases |
| Mr. Chris Barrett | Sr. VP of Commercial Strategy, Common Disease |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.2225 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-09-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |